Home › Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
 

Keywords :   


Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine

2016-05-03 02:52:15| drugdiscoveryonline News Articles

Trevena, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, recently announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA)

Tags: for program meeting successful

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Amazon says workers must be in the office. The UK government disagrees. Who is right?
22.09Eastern North Pacific Tropical Weather Outlook
22.09Atlantic Tropical Weather Outlook
21.09Atlantic Tropical Weather Outlook
More »